Bode Anna, Borja Montes Oscar F, SantaCruz Karen, Baker Sheikh Abu
Department of Internal Medicine, University of New Mexico, Albuquerque, USA.
Department of Pathology, University of New Mexico, Albuquerque, USA.
Eur J Case Rep Intern Med. 2025 Apr 3;12(5):005229. doi: 10.12890/2025_005229. eCollection 2025.
Monoclonal gammopathies encompass many types of plasma cell proliferative disorders ranging from benign to malignant. Monoclonal gammopathies that meet diagnostic criteria for monoclonal gammopathies of undetermined significance (MGUS) but with clinical manifestations are now being referred to as monoclonal gammopathies of clinical significance (MGCS). MGUS associated myopathies are a rare form of MGCS.
We present a case of MGUS associated necrotizing myositis. The patient had been previously diagnosed with MGUS and myositis around the same time, but prior testing had not revealed the etiology of the myopathy. Repeat biopsy and work-up revealed a necrotizing myopathy.
MGUS associated myopathies are rare, with the most common being sporadic late-onset nemaline myopathy (SLONM-MGUS) and amyloid light chain (AL) amyloidosis-associated myopathy. MGUS associated necrotizing myopathy is even rarer. Because this condition is so uncommon, there are no standardized guidelines on how to treat this condition. Some case reports or studies suggest treating the myositis with standard of care for the myositis type without considering the monoclonal gammopathy while other studies have suggested that treating the monoclonal gammopathy would be beneficial in treating the associated clinical syndrome.
Our case report of MGUS associated necrotizing myopathy encourages internists to broaden their differential diagnosis of myopathy, increasing awareness of a condition that is still not well understood.
Monoclonal gammopathy of clinical significance is a new term that refers to nonmalignant monoclonal gammopathies that exhibit significant clinical manifestations.Monoclonal gammopathy associated myopathies are rare but should be considered as part of the differential diagnosis for myopathy.
单克隆丙种球蛋白病涵盖多种从良性到恶性的浆细胞增殖性疾病。符合意义未明的单克隆丙种球蛋白病(MGUS)诊断标准但有临床表现的单克隆丙种球蛋白病现被称为具有临床意义的单克隆丙种球蛋白病(MGCS)。MGUS相关肌病是MGCS的一种罕见形式。
我们报告一例MGUS相关坏死性肌炎病例。该患者此前在同一时间被诊断为MGUS和肌炎,但之前的检查未揭示肌病的病因。再次活检及进一步检查发现为坏死性肌病。
MGUS相关肌病较为罕见,最常见的是散发性迟发性杆状体肌病(SLONM-MGUS)和淀粉样轻链(AL)淀粉样变性相关肌病。MGUS相关坏死性肌病更为罕见。由于这种情况非常罕见,目前尚无关于如何治疗该病的标准化指南。一些病例报告或研究建议按照肌炎类型的标准治疗方案治疗肌炎,而不考虑单克隆丙种球蛋白病,而其他研究则表明治疗单克隆丙种球蛋白病对治疗相关临床综合征有益。
我们关于MGUS相关坏死性肌病的病例报告促使内科医生拓宽对肌病的鉴别诊断范围,提高对这种仍未被充分了解的疾病的认识。
具有临床意义的单克隆丙种球蛋白病是一个新术语,指表现出显著临床表现的非恶性单克隆丙种球蛋白病。单克隆丙种球蛋白病相关肌病虽罕见,但应作为肌病鉴别诊断的一部分予以考虑。